Molecular Medicine Reports Molecular Medicine Reports 1791-2997 1791-3004 D.A. Spandidos 10.3892/mmr.2021.12268 MMR-0-0-12268 Articles Oxaliplatin promotes siMAD2L2-induced apoptosis in colon cancer cells MaLu 1 2 * LiXin 1 2 * ZhaoXiaopeng 1 2 SunHaotong 1 2 KongFeifei 3 LiYuanjie 1 2 SuiYu 1 2 XuFang 1 2 Department of Medical Genetics and Cell Biology, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China Key Laboratory of Reproduction and Genetics, Ningxia Medical University, Yinchuan, Ningxia 750004, P.R. China Department of Oncology, Qufu People's Hospital, Qufu, Shandong 273100, P.R. China Correspondence to: Professor Fang Xu, Department of Medical Genetics and Cell Biology, School of Basic Medical Sciences, Ningxia Medical University, 1160 Shengli Street, Xingqing, Yinchuan, Ningxia 750004, P.R. China, E-mail: xufang@nxmu.edu.cn

Contributed equally

 09 2021 05 07 2021 24 3 629 15092020 26052021 Copyright: © Ma et al. 2021 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The clinical efficacy of colorectal tumor treatment is restricted due to platinum agent resistance. Translesion DNA synthesis (TLS) has been shown to contribute to this resistance; however, the exact molecular mechanism remains unknown. The present study aimed to investigate the possible function of the core of the TLS polymerase mitotic arrest deficient 2 like 2 (MAD2L2) in drug sensitivity, in order to provide a treatment rationale for platinum-based chemotherapy in colon cancer. In the present study, MAD2L2 was knocked down using MAD2L2-specific small interfering (si)RNA. HCT116 and SW620 cells were treated with oxaliplatin and MG132; oxaliplatin is a platinum compound that induces DNA damage and MG132 is a potent proteasome inhibitor. Cell viability was determined using an MTT assay. Cell apoptosis was examined via flow cytometry and TUNEL assay. The activity of proteasome 26S subunit, non-ATPase 13 (PSMD13) was detected using ELISA, while the expression levels of apoptotic-related proteins were detected via western blotting. The results demonstrated that cells treated with oxaliplatin or MG132 alone had decreased viability, but a synergistic effect was not observed after co-treatment. In addition, the knockdown of MAD2L2 caused by siMAD2L2 or oxaliplatin treatment increased the expression levels of the pro-apoptotic proteins Bax and Bak and decreased the expression levels of the anti-apoptotic protein Bcl-2, compared with the negative control group. Moreover, MG132 alleviated the decrease in MAD2L2 expression, while reducing siMAD2L2-induced cell apoptosis. These results indicate that oxaliplatin promotes siMAD2L2-induced apoptosis in colon cancer cells. This process was associated with the Bcl-2 and ubiquitin-proteasome pathway. Overall, the present study provides a theoretical basis for improving the clinical efficacy of colon cancer by combining chemotherapy and gene therapy.

 mitotic arrest deficient 2 like 2 oxaliplatin colon cancer cell ubiquitin-proteasome pathway cell apoptosis National Natural Science Foundation of Chinahttp://dx.doi.org/10.13039/501100001809 31360251 West China first-class Disciplines Basic Medical Sciences at Ningxia Medical University NXYLXK2017B07 The present study was supported by the National Natural Science Foundation of China (grant no. 31360251) and West China first-class Disciplines Basic Medical Sciences at Ningxia Medical University (grant no. NXYLXK2017B07). Introduction

Globally, colorectal cancer (CRC) is the third most common form of cancer, and is the second most common cause of cancer-associated mortality (1,2). Although CRC is considered to be mainly prevalent in developed countries, the incidence is also rising rapidly in developing countries (3,4). Further basic and clinical research would undoubtedly accelerate the progress in the treatment of CRC.

Oxaliplatin has been proven for its specificity against colorectal tumors, thereby becoming a standard therapeutic in the management of this malignancy (5). However, its clinical application is restricted due to drug resistance and toxic side effects (6). Although research has been conducted through laboratory-based and clinical studies to improve and optimize therapeutic potency, high efficiency and safe treatment options remain the focus of ongoing studies. In recent years, chemotherapeutic drugs and gene-based combination therapy have become one of the most promising and active research fields in medicine (7).

Oxaliplatin functions predominantly via the formation of drug-DNA adducts that block DNA synthesis, thereby triggering a cellular response and eventually leading to cell apoptosis (8). Translesion DNA synthesis (TLS) is a strategy for tolerating DNA damage, which serves an essential role in the maintenance of genome stability (9). Recent studies have revealed that TLS polymerase contributes to the development of platinum resistance in cancer cells (10), particularly polymerase ζ (11). REV3, the catalytic subunit of polymerase ζ, has attracted increased attention from researchers and a series of related reports can be found (12–15), while another subunit, mitotic arrest deficient 2 like 2 (MAD2L2; also known as REV7), has been rarely studied (11).

The ubiquitin (Ub) proteasome pathway (UPP) is the most important pathway involved in intracellular protein degradation (16). The 26S proteasome is an essential multi-catalytic protease complex, which serves key roles in the function of the UPP. The 26S proteasome consists of proteasome 26S subunit, non-ATPase 13 (PSMD13) and a few additional components, such as proteasomal Ub receptor, proteasome 26S subunit, ATPase 1, Ub specific peptidase 14 and Ub C-terminal hydrolases 37 (17,18). Specific proteins involved in DNA damage repair, cell cycle regulation and apoptosis are the targets of the UPP (19). However, the underlying regulatory mechanism between the expression level of MAD2L2 and the UPP has not yet been elucidated. The current study proposed that the UPP may be involved in DNA damage repair of tumor cells caused by TLS and oxaliplatin, which may be mediated by regulating the expression levels of MAD2L2, thereby affecting cell apoptosis. MG132, a specific inhibitor of the 26S proteasome, was selected as an appropriate experimental compound to be used in the present study.

The present study aimed to investigate the antitumor effect and possible mechanism of MAD2L2, in order to provide a rationale for the clinical treatment of colon cancer.

 Materials and methods <sec> <title>Cell culture and treatment

Colon cancer cell lines, HCT116 and SW620, were obtained from the American Type Culture Collection. Cells were incubated in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and Penicillin-Streptomycin Solution (10,000 U/ml; Beyotime Institute of Biotechnology) at 37°C and 5% CO2.

Gene expression was knocked down using small interfering (si)RNA. Cells were transfected with 10 µM MAD2L2 siRNA and negative control siRNA using Lipofectamine® RNAi MAX (Invitrogen; Thermo Fisher Scientific, Inc.) at 37°C for 48 h. siRNA were designed and synthesized by Shanghai GenePharma Co., Ltd. The siRNA sequences were as follows: MAD2L2 forward, 5′-AAGAUGCAGCUUUACGUGGAATT-3′ and reverse, 5′-UUCCACGUAAAGCUGCAUCUUTT-3′; and negative control forward, 5′-UUCUCCGAACGUGUCACGUTT-3′ and reverse, 5′-ACGUGACACGUUCGGAGAATT-3′. Reverse transcription-quantitative PCR (RT-qPCR) and western blotting were performed to identify transfection efficiency after 48-h transfection.

Cells were treated with oxaliplatin(Jiangsu Hengrui Medicine Co., Ltd.) and MG132 (MedChemExpress) at 37°C for 24 h. The concentrations of both drugs under the current experimental condition were recalculated according to previous studies: Oxaliplatin, 50 µM in HCT116 cells and 90 µM in SW620 cells; and MG132, 18 µM in HCT116 cells and 36 µM in SW620 cells. As a control, the blank group received the same volume of 1% dimethyl sulfoxide (DMSO) vehicle as the other groups.

 RT-qPCR

RT-qPCR was performed to detect and quantify mRNA. Total RNA was extracted from experimental cells using TRIzol® reagent (Beyotime Institute of Biotechnology). cDNA was produced using SYBR Premix Ex TaqII (TliRNaseH Plus; Takara Biotechnology Co., Ltd.) from the extracted RNA. RT reactions were conducted under the following conditions: 37°C for 15 min, 85°C 5 sec, maintained at 4°C. qPCR amplification reactions were carried out in the Applied Biosystems™ 7500 Fast Real Time PCR system using a PowerUp™ SYBR™ Green Master Mix (both Thermo Fisher Scientific, Inc.). Available primers were obtained from Sangon Biotech, Co., Ltd., and the sequences of primers are as follows: MAD2L2 forward, 5′-CCAGGCTGTACCTTCACAGTC-3′ and reverse, 5′-TCTTCCACGTAAAGCTGCATC-3′; and GAPDH forward, 5′-ACCCACTCCTCCACCTTTGAC-3′ and reverse, 5′-CACCACCCTGTTGCTGTAGCC-3′. The thermocycling conditions were as follows: Initial denaturation at 95°C for 2 min; followed by 40 cycles of denaturation at 95°C for 3 sec and annealing/elongation at 60°C for 30 sec; followed by a final extension step at 60°C for 1 min. Finally, the relative gene expression values were calculated using the 2−∆∆Cq method (20).

 Western blotting

Western blotting was performed to separate and identify proteins. Total proteins were extracted using RIPA buffer (Beyotime Institute of Biotechnology), followed by the determination of the protein concentration using a BCA kit (Nanjing KeyGen Biotech. Co., Ltd.). Proteins (20–30 µg/well) were separated via 12% SDS-PAGE at 120 V and then transferred into 0.2-µm PVDF membrane under wet conditions at 300 mA. The blotted membranes were blocked with 5% non-fat milk for 2 h at room temperature. Antibodies were diluted in TBS-Tween-20 (1% TBS and 0.1% Tween). Primary antibodies were incubated at 4°C overnight and secondary antibodies were incubated at room temperature for 1 h. Chemiluminescent signals were detected using Pierce™ ECL Western Blotting substrate (cat. no. 32109; Thermo Fisher Scientific, Inc.). Images were captured using Bio-Rad ChemiDOC XRS+ system (Bio-Rad Laboratories, Inc.) and analyzed by Image Lab Software (version 5.2.1; Bio-Rad Laboratories, Inc.). The following antibodies were used: Primary antibodies, MAD2L2 (cat. no. sc135977; 1:500; Santa Cruz Biotechnology, Inc.), PSMD13 (cat. no. ab229812; 1:1,000; Abcam), Bax (cat. no. bs-0127R; 1:200; BIOSS), Bak (cat. no. bs-1284R; 1:200; BIOSS), Bcl-2 (cat. no. bs-0032R; 1:200; BIOSS) and GAPDH (cat. no. AB-P-R 001; 1:1,000; Hangzhou Goodhere Biotechnology Co., Ltd.); Secondary antibodies, goat Anti-Rabbit IgG H&L (HRP) (cat. no. ab6721; 1:10,000; Abcam) and goat Anti-Mouse IgG H&L (HRP) (cat. no. ab205719; 1:10,000; Abcam).

 MTT assay

Cell viability was investigated using an MTT assay kit (Nanjing KeyGen Biotech Co., Ltd.). The cell count was adjusted to 1×104 cells/ml. Cells were treated with oxaliplatin and MG132 in 96-well plate at 37°C for 24 h. MTT solution was added and incubated for 30 min at 37°C until the solution turned purple. DMSO was used for dissolving the purple crystals. Absorbance was measured using Multiskan™ GO microplate spectrophotometer (Thermo Fisher Scientific, Inc.) at 570 nm. The percentage of cell viability was calculated.

 Flow cytometry

Cell apoptosis was detected via flow cytometry (BD Accuri™ C6; BD Biosciences). EDTA-free trypsin (Hyclone Laboratories, Inc.) was used to detach the experimental cells. According to the instructions of the Annexin V-FITC/PI kit (BD Biosciences), each group of cells was incubated with 5 µl Annexin V-FITC for 15 min at 2–8°C. Subsequently, 10 µl PI was added and incubated for 5 min at 2–8°C. Cells were analyzed within 30 min after staining using BD Accuri C6 software (version 5.0; BD Biosciences). The apoptotic rate was calculated as the percentage of early and late apoptotic cells.

 TUNEL assay

DNA fragmentation, which is a marker of cell apoptosis (2), was detected using the TUNEL BrightGreen Apoptosis Detection kit (cat. no. A112-02; Vazyme Biotech Co., Ltd.). The cells were cultured on microscope slides, fixed with 4% formaldehyde at room temperature for 15 min and permeabilized with 0.25% Triton®X-100 at room temperature for 20 min. TUNEL staining was performed according to the manufacturer's instructions; cells were stained with 50 µl Recombinant TdT Enzyme at 37°C for 60 min and with 50 µl BrightGreen Labeling Mix at 37°C for 60 min. The slides were then immersed into 2 µg/ml DAPI solution and stained in the dark for 5 min. The samples were examined via fluorescence microscopy (DFC450 C; Leica Microsystems, Inc.); 10 visual fields were randomly selected per slide at ×400 magnification.

 ELISA

Total cell protein was extracted using RIPA buffer (Beyotime Institute of Biotechnology) from experimental cells. The activity of PSMD13 was detected using an ELISA kit (cat. no. ml-55255; Enzyme-linked Biotechnology Co., Ltd.). According to the manufacturer's instructions, standard wells, testing sample wells and blank wells were set. Standard and blank proteins were obtained from the ELISA kit. Standard protein was diluted to a range of 0, 50, 100, 150, 200, 250 and 300 ng/ml. Each concentration of these standard samples was added to standard wells, 50 µl/well; extracted protein samples were added to the testing well, 50 µl/well; And 50 µl blank protein was added to the blank well. Subsequently, 80 µl HRP-conjugated antibody was immediately added to the wells and incubated at 37°C for 1 h. Chromogenic substrate A (50 µl) and chromogenic substrate B (50 µl) were added and incubated at 37°C for 10 min, in the dark. Finally, 50 µl stop solution were added to each well to terminate the reaction. The optical density was measured at 450 nm. A standard curve was constructed and the corresponding concentration of PSMD13 was calculated.

 Statistical analysis

SPSS 21.0 (IBM Corp.) was used for statistical analysis and GraphPad Prism 5 (GraphPad Software, Inc.) was used to generate the figures and mark the statistical difference. Data are presented as the mean ± SD. An unpaired Student's t-test was used for comparison between two independent samples. One-way ANOVA was used for comparisons between groups, followed by Tukey's multiple comparisons test as the post-hoc test. P<0.05 was considered to indicate a statistically significant difference. All experiments were repeated ≥3 times.

 Results <sec> <title>MAD2L2 is regulated by oxaliplatin and MG132 in human colon cancer cells

Cells were treated with oxaliplatin and MG132. The MTT data indicated that cells treated with oxaliplatin or MG132 had a significant decrease in their viability compared with the blank group, but a synergistic effect was not observed during the co-treatment of oxaliplatin and MG132 (Table I). The western blotting results demonstrated that oxaliplatin and MG132 caused a significant decrease in the protein expression level of MAD2L2, but a synergistic effect was not observed in the co-treatment group (Fig. 1). These results indicated that the expression level of MAD2L2 was decreased by oxaliplatin and MG132 in human colon cancer cells, but no synergistic effects were observed.

 Knockdown of MAD2L2 promotes Bcl-2-mediated apoptosis of colon cancer cells

Since oxaliplatin and MG132 were identified to affect the expression level of MAD2L2, the associations between them were investigated. Cells were transfected with siMAD2L2; compared with the negative control group, the mRNA expression levels of MAD2L2 were significantly downregulated in the siMAD2L2 group (Fig. 2). Subsequently, the experimental cells were treated with oxaliplatin and MG132. The MTT data revealed that, compared with the negative control group, siMAD2L2 caused a significant decrease in cell viability (Table II). Compared with the siMAD2L2 group, cell viability was suppressed by the co-treatment of siMAD2L2 and oxaliplatin, whereas it was increased by the co-treatment of siMAD2L2 and MG132. A synergistic effect was not observed during triple co-treatment with siMAD2L2, oxaliplatin and MG132 (Table II).

As shown by western blotting, compared with negative control group, siMAD2L2 significantly increased the expression levels of the pro-apoptotic proteins Bax and Bak, as well as decreased the expression level of the anti-apoptotic protein Bcl-2 (Fig. 3). Compared with siMAD2L2 group, cells co-treated with siMAD2L2 and oxaliplatin had increased Bax and Bak expression, and increased Bcl-2 expression. Compared with siMAD2L2 and oxaliplatin co-treatment group, the expression levels of Bax and Bak were significantly decreased after co-treatment with siMAD2L2, oxaliplatin and MG132, while Bcl-2 expression was higher (Fig. 3). This apoptotic effect was further confirmed by the flow cytometry and TUNEL assay results (Figs. 4 and 5). These observations suggested that the Bcl-2 pathway may be involved in the cell apoptosis mediated by MAD2L2.

 siMAD2L2-induced suppression of PSMD13 is regulated by oxaliplatin and MG132

Previous studies reported that DNA damage-induced cytotoxic effects were inhibited by MG132 (21–23). Therefore, the activity of PSMD13, a key protein of the UPP, was evaluated via ELISA. The results demonstrated that, compared with the negative control group, the activity and expression level of PSMD13 protein were significantly increased in the siMAD2L2 group. Compared with the siMAD2L2 group, PSMD13 activity was mitigated by the co-treatment of siMAD2L2 and MG132, whereas it was promoted by the co-treatment of siMAD2L2 and oxaliplatin. A synergistic effect was not observed during triple co-treatment with siMAD2L2, oxaliplatin and MG132 (Table III), and this effect was further confirmed via western blotting (Fig. 6). These observations indicated that the UPP was involved in the regulation of TLS.

 Discussion

MAD2L2, also called REV7 or MAD2B, encodes a core subunit of DNA polymerase ζ (24). Previous studies have reported that, in addition to maintaining genomic stability, MAD2L2 was also involved in multiple cellular functions, such as drug resistance reversal, epithelial stromal transformation transcription and signal transduction events (25–27). In the present study, the aim was to investigate the effects of MAD2L2-induced cell apoptosis.

Previous studies have shown that DNA polymerase ζ plays an important role in the regulation of platinum resistance and REV3 has been considered the main focus (28); however, the role of MAD2L2 has been underestimated. In the present study, MAD2L2 was selected as the target gene; the results revealed that MAD2L2 promoted oxaliplatin-induced apoptosis. In the present study, human colon cancer cells, HCT116 and SW620, were selected. Cells were characterized for DNA damage by oxaliplatin. The protein expression level of MAD2L2 was found to be significantly downregulated. Flow cytometry and TUNEL results demonstrated that treatment with siMAD2L2 or oxaliplatin alone increased the apoptosis of both HCT116 and SW620 cells, whereas cells co-treated with siMAD2L2 and oxaliplatin significantly promoted apoptosis. The results of western blotting showed that knockdown of MAD2L2 expression caused by RNA interference or oxaliplatin increased the expression levels of pro-apoptotic proteins Bax and Bak and decreased the expression levels of anti-apoptotic protein Bcl-2, compared with the negative control group. These results indicated that oxaliplatin promoted siMAD2L2-induced apoptosis of colon cancer cells, and this process was associated with the Bcl-2 family mediated cell apoptosis pathway.

In order to investigate the causes of MAD2L2-induced cell apoptosis, the present study focused on the UPP, which is responsible for the majority of intracellular protein degradation (29). This system exerts its biological effect via the cooperation of E1/E2/E3. Ub is activated by E1 and is then transferred to E2, which permits it to be sequentially conjugated to E3. E3 recognizes target substrates and catalyzes the covalent attachment of Ub to it (30). Finally, the substrates modified with polyubiquitin chains are delivered to the 26S proteasome for proteolytic destruction. Here, PSMD13 serves an important role (31).

In the present study, the activity of PSMD13 was evaluated via ELISA and further confirmed by western blotting. The results showed that the activity and protein expression level of PSMD13 were significantly increased by siMAD2L2. In addition, MG132, the inhibitor of proteasome, decreased the expression of MAD2L2, while reducing the siMAD2L2-induced cell apoptosis. These results suggest that the UPP was implicated in the regulation of TLS.

TLS depends on the orderly assembly of DNA polymerases (32). Cells are constantly exposed to DNA damage agents, such as UV, methyl methanesulfonate and other cytotoxic factors (33). Once DNA damage occurs, proliferating cell nuclear antigen (PCNA) can be recruited and mono-ubiquitinated by Rad18-Rad6 at Lys164 (K164), and Ub-PCNA mediates cellular response by TLS polymerases (34,35). MAD2L2 helps to coordinate the nucleotide insertion and extension steps of lesion bypass (36). Interestingly, Rad18 and Rad6 are particularly important E2 and E3 enzymes, which function as Ub conjugating and Ub ligase enzymes, respectively, and have been shown to be involved in the UPP, which mediates the degradation of proteins (37).

In the present study, the protein expression level of MAD2L2 was inhibited when the cells were treated with MG132. In addition, cell apoptosis was reduced by MG132 compared with the co-treatment of siMAD2L2 and oxaliplatin. Based on these results, it was suggested that the UPP may be one of the responders of TLS-related DNA damage in colon cancer cells. DNA lesions that are induced by oxaliplatin or siMAD2L2 may promote the cooperation between Rad6 and Rad18, which then activate PSMD13, finally resulting in the degradation of MAD2L2 protein. Such agents arrest TLS, trigger the accumulation of DNA damage and promote cancer cell apoptosis (38).

Although the present study indicated that both oxaliplatin and MG132 exerted impacts on siMAD2L2-induced cell apoptosis, these factors were not simply synergistic or antagonistic. More direct evidence is needed for effective treatment of colon cancer in the future. In conclusion, the present study demonstrated oxaliplatin promoted siMAD2L2-induced colon cell apoptosis, which was regulated by the UPP. Overall, the present study provides a theoretical basis for improving the clinical efficacy of colon cancer by combining chemotherapy and gene therapy.

 Acknowledgements

I would like to extend my sincere gratitude to Professor Hao Wang (School of Pharmacy, Minzu University of China), Professor Jianmin Sun (School of Basic Medical Sciences, Ningxia Medical University) for their intellectual guidance, valuable comments and enlightening suggestions for my study and manuscript preparation.

 Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 31360251) and West China first-class Disciplines Basic Medical Sciences at Ningxia Medical University (grant no. NXYLXK2017B07).

 Availability of data and materials

The datasets used during the current study are available from the corresponding author on reasonable request.

 Authors' contributions

LM and FX designed the study. YL performed cell culture, transfection experiments and drug sensitivity tests. HTS contributed to the ELISA and western blotting assays. XPZ and XL performed the flow cytometry and TUNEL assays. LM and HTS acquired and interpretated the data. FFK and YS assisted with data analysis. LM, XL and YL drafted the manuscript. HTS and LM are responsible for confirming the authenticity of the raw data. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References SiegelRLMillerKDJemalACancer statistics, 2020CA Cancer J Clin70730202010.3322/caac.2160131912902 CrowleyLCMarfellBJWaterhouseNJDetection of DNA fragmentation in apoptotic cells by TUNELCold Spring Harb Protoc20162016 ZhouJZhengRZhangSZengHWangSChenRSunKLiMGuJZhuangGWeiWColorectal cancer burden and trends: Comparison between China and major burden countries in the worldChin J Cancer Res33110202110.21147/j.issn.1000-9604.2021.01.0133707923 National Health Commission Of The People's Republic Of ChinaNational guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version)Chin J Cancer Res32415445202010.21147/j.issn.1000-9604.2020.04.0132965276 SharmaGAnghoreDKhareRRawalRKOxaliplatin for colorectal cancer therapy: A reviewClin Cancer Drugs51327201810.2174/2212697X0566618090509494229977507 BrownAKumarSTchounwouPBCisplatin-based chemotherapy of human cancersJ Cancer Sci Ther1197201932148661 McQuadeRMStojanovskaVBornsteinJCNurgaliKColorectal cancer chemotherapy: The evolution of treatment and new approachesCurr Med Chemistry2415371557201710.2174/092986732466617011115243628079003 SigelARiddellIALippardSJSigelHFreisingerESigelRKOCisplatin and oxaliplatin: Our current understanding of their actions142201829218638 MaXTangTSGuoCRegulation of translesion DNA synthesis in mammalian cellsEnviron Mol Mutagen61680692202010.1002/em.2235931983077 ShanbhagVSachdevSFloresJAModakMJSinghKFamily A and B DNA polymerases in cancer: Opportunities for therapeutic interventionsBiology (Basel)75201829301327 SharmaSShahNAJoinerAMRobertsKHCanmanCEDNA polymerase zeta is a major determinant of resistance to platinum-based chemotherapeutic agentsMol Pharmacol81778787201210.1124/mol.111.07682822387291 JiangHGChenPSuJYWuMQianHWangYLiJKnockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cellsJ Cell Physiol23234333443201710.1002/jcp.2579228075014 MalikRKopylovMGomez-LlorenteYJainRJohnsonREPrakashLPrakashSUbarretxena-BelandiaIAggarwalAKStructure and mechanism of B-family DNA polymerase zeta specialized for translesion DNA synthesisNat Struct Mol Biol27913924202010.1038/s41594-020-0476-732807989 WashingtonMTGildenbergMSStructure of DNA polymerase ζ: Capturing the getaway driverNat Struct Mol Biol2712202010.1038/s41594-020-0502-932843752 SuzukiTSassaAGruzPGuptaRCJohnsonFAdachiNNohmiTError-prone bypass patch by a low-fidelity variant of DNA polymerase zeta in human cellsDNA Repair (Amst)100103052202110.1016/j.dnarep.2021.10305233607474 GaczynskaMOsmulskiPATargeting protein-protein interactions in the ubiquitin-proteasome pathwayAdv Protein Chem Struct Biol110123165201810.1016/bs.apcsb.2017.09.00129412995 BiWZhuLZengZJingXLiangYGuoLShiQXuATaoEInvestigations into the role of 26S proteasome non-ATPase regulatory subunit 13 in neuroinflammationNeuroimmunomodulation21331337201410.1159/00035781124642793 BardJAMGoodallEAGreeneERJonssonEDongKCMartinAStructure and function of the 26S proteasomeAnn Rev Biochem87697724201810.1146/annurev-biochem-062917-01193129652515 ChenXHtetZMLopez-AlfonzoEMartinAWaltersKJProteasome interaction with ubiquitinated substrates: From mechanisms to therapiesFEBS JNov192020(Epub ahead of print)10.1111/febs.15638 LivakKJSchmittgenTDAnalysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) methodMethods25402408200110.1006/meth.2001.126211846609 TuYChenCPanJXuJZhouZGWangCYThe Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesisInt J Clin Exp Pathol5726738201223071855 SakaiWYuasa-SunagawaMKusakabeMKishimotoAMatsuiTKanekoYAkagiJIHuygheNIkuraMIkuraTFunctional impacts of the ubiquitin-proteasome system on DNA damage recognition in global genome nucleotide excision repairSci Rep1019704202010.1038/s41598-020-76898-233184426 RamadanKMeerangMDegradation-linked ubiquitin signal and proteasome are integral components of DNA double strand break repair: New perspectives for anti-cancer therapyFEBS Lett58528682875201110.1016/j.febslet.2011.04.04621536036 RizzoAAVasselFMChatterjeeND'SouzaSLiYHaoBHemannMTWalkerGCKorzhnevDMRev7 dimerization is important for assembly and function of the Rev1/Polζ translesion synthesis complexProc Natl Acad Sci USA115E8191E8200201810.1073/pnas.180114911530111544 FengLWeiWHengZYantaoHChunboWKnockdown of REV7 inhibits breast cancer cell migration and invasionOncol Res24315325201610.3727/096504016X1466699034759027712588 RosenbergSCCorbettKDThe multifaceted roles of the HORMA domain in cellular signalingJ Cell Biol211745755201510.1083/jcb.20150907626598612 HaraKTaharazakoSIkedaMFujitaHMikamiYKikuchiSHishikiAYokoyamaHIshikawaYKannoSIDynamic feature of mitotic arrest deficient 2-like protein 2 (MAD2L2) and structural basis for its interaction with chromosome alignment-maintaining phosphoprotein (CAMP)J Biol Chem2921765817667201710.1074/jbc.M117.80423728887307 SandersMAHaynesBNangia-MakkerPPolinLAShekharMPPharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugsJ Biol Chemistry2921034710363201710.1074/jbc.M117.79219228490629 JantrapiromSPiccoloLLPruksakornDPotikanondSNimlamoolWUbiquilin networking in cancersCancers1212061586202010.3390/cancers1206158632549375 LeestemakerYOvaaHTools to investigate the ubiquitin proteasome system. Drug discovery todayTechnologies262531201729249239 WehmerMRudackTBeckFAufderheideAPfeiferGPlitzkoJMFörsterFSchultenKBaumeisterWSakataEStructural insights into the functional cycle of the ATPase module of the 26S proteasomeProc Natl Acad Sci USA11413051310201710.1073/pnas.162112911428115689 RizzoAAKorzhnevDMThe Rev1-Polζ translesion synthesis mutasome: Structure, interactions and inhibitionEnzymes45139181201910.1016/bs.enz.2019.07.00131627876 FernandesEFonsecaTGCarriçoTMestreNTavaresÁBebiannoMJCytotoxic responses of the anticancer drug cyclophosphamide in the mussel Mytilus galloprovincialis and comparative sensitivity with human cells linesChemosphere261127678202010.1016/j.chemosphere.2020.12767832717509 KanaoRMasutaniCRegulation of DNA damage tolerance in mammalian cells by post-translational modifications of PCNAMutat Res803-8058288201710.1016/j.mrfmmm.2017.06.00428666590 LauWCYLiYZhangQHuenMSYMolecular architecture of the Ub-PCNA/Pol η complex bound to DNASci Rep515759201510.1038/srep1575926503230 QuinetALernerLKMartinsDJMenckCFMFilling gaps in translesion DNA synthesis in human cellsMutat Res Genet Toxicol Environ Mutagen836127142201810.1016/j.mrgentox.2018.02.00430442338 AnHYangLWangCGanZGuHZhangTHuangXLiuYLiYChangSJInteractome analysis reveals a novel role for RAD6 in the regulation of proteasome activity and localization in response to DNA damageMol Cell Biol37e00419e00416201710.1128/MCB.00419-16 MasudaYMasutaniCSpatiotemporal regulation of PCNA ubiquitination in damage tolerance pathwaysCrit Rev Biochem Mol Biol54418442201910.1080/10409238.2019.168742031736364

MAD2L2 expression is downregulated by oxaliplatin and MG132 in human colon cancer cells. (A) Western blotting was performed to detect the protein expression levels of MAD2L2 in HCT116 and SW620 cells. The cells were treated with oxaliplatin or MG132 alone, or co-treated with oxaliplatin + MG132 for 24 h (oxaliplatin was incubated at 50 and 90 µM with HCT116 and SW620 cells, respectively; MG132 was incubated at 18 and 36 µM with HCT116 and SW620 cells, respectively). One-way ANOVA followed by Tukey's multiple comparisons test was used to determine the statistical significance in (B) HCT116 and (C) SW620 cells. The data are presented as mean ± SD. n=3. **P<0.01, ***P<0.001 vs. blank. MAD2L2, mitotic arrest deficient 2 like 2.

siMAD2L2 transfection downregulates the expression levels of MAD2L2 in human colon cancer cells. Negative siRNA and siMAD2L2 sequences were separately transfected into the cells, which were incubated for 24 h. Reverse transcription-quantitative PCR analysis was performed to identify the transfection efficiency. The mRNA expression levels of MAD2L2 were assessed in (A) HCT116 and (B) SW620 cells. An unpaired Student's t-test was used to determine the statistical significance of the differences between the groups. The data are presented as the mean ± SD. n=3. **P<0.01, ***P<0.001 vs. negative. MAD2L2, mitotic arrest deficient 2 like 2; si, small interfering RNA.

Knockdown of MAD2L2 expression promotes Bcl-2-mediated apoptosis of colon cancer cells. The cells were treated with negative siRNA, siMAD2L2, siMAD2L2 + oxaliplatin, siMAD2L2 + MG132 and siMAD2L2 + oxaliplatin + MG132 (oxaliplatin was incubated for 24 h at 50 and 90 µM with HCT116 and SW620 cells, respectively; MG132 was incubated for 24 h at 18 and 36 µM with HCT116 and SW620 cells, respectively). Western blotting was performed to detect the expression levels of cell apoptosis-associated proteins. (A) Expression levels of Bax, Bak and Bcl-2 proteins in HCT116 and SW620 cells. One-way ANOVA followed by Tukey's multiple comparisons test was used to determine the statistical significance in (B) HCT116 and (C) SW620 cells. The data are presented as the mean ± SD. n=3. *P<0.05 vs. negative group; $P<0.05 vs. siMAD2L2 group; &P<0.05 vs. siMAD2L2 + oxaliplatin group; #P<0.05 vs. siMAD2L2 + MG132 group. MAD2L2, mitotic arrest deficient 2 like 2; si, small interfering RNA.

siMAD2L2-induced cell apoptosis is regulated by oxaliplatin and MG132 in HCT116 and SW620 cells. The cells were treated with oxaliplatin or MG132 alone, or co-treated with oxaliplatin and MG132 for 24 h (oxaliplatin was incubated at 50 and 90 µM with HCT116 and SW620 cells, respectively; MG132 was incubated at 18 and 36 µM with HCT116 and SW620 cells, respectively). The induction of cell apoptosis was determined via flow cytometry. MAD2L2, mitotic arrest deficient 2 like 2; si, small interfering RNA.

siMAD2L2-induced cell apoptosis is regulated by oxaliplatin and MG132 in HCT116 and SW620 cells. The cells were treated with oxaliplatin or MG132 alone, or co-treated with oxaliplatin and MG132 for 24 h (oxaliplatin was incubated at 50 and 90 µM with HCT116 and SW620 cells, respectively; MG132 was incubated at 18 and 36 µM with HCT116 and SW620 cells, respectively). The induction of cell apoptosis was determined using TUNEL staining. Scale bar, 40 µm. MAD2L2, mitotic arrest deficient 2 like 2; si, small interfering RNA.

siMAD2L2-induced suppression of PSMD13 is regulated by oxaliplatin and MG132. The cells were treated with negative siRNA, siMAD2L2, siMAD2L2 + oxaliplatin, siMAD2L2 + MG132, siMAD2L2 + oxaliplatin + MG132 (oxaliplatin was incubated for 24 h at 50 and 90 µM with HCT116 and SW620 cells, respectively; MG132 was incubated for 24 h at 18 and 36 µM with HCT116 and SW620 cells, respectively). (A) Western blotting was performed to detect the protein levels of PSMD13 in HCT116 and SW620 cells. One-way ANOVA followed by Tukey's multiple comparisons test was used to determine the statistical significance in (B) HCT116 and (C) SW620 cells. The data are presented as the mean ± SD. n=3. *P<0.05 vs. negative group; $P<0.05 vs. siMAD2L2 group; &P<0.05 vs. siMAD2L2 + oxaliplatin group; #P<0.05 vs. siMAD2L2 + MG132 group. MAD2L2, mitotic arrest deficient 2 like 2; si, small interfering RNA; PSMD13, proteasome 26S subunit, non-ATPase 13.

Effects of oxaliplatin and/or MG132 on the viability of human colorectal cancer cells.

Cells Blank Oxaliplatin MG132 Oxaliplatin and MG132
HCT116 0.904±0.001 0.656±0.043a 0.257±0.011a 0.351±0.005a
SW620 0.909±0.0002 0.665±0.011a 0.215±0.006a 0.258±0.007a

P<0.001 vs. blank group. The data are presented as the mean ± SD. n=3. The cells were treated with oxaliplatin or MG132 alone, or co-treated with oxaliplatin and MG132 for 24 h (oxaliplatin was administered at 50 and 90 µM to HCT116 and SW620 cells, respectively; MG132 was administered at 18 and 36 µM to HCT116 and SW620 cells, respectively). Cell viability was assessed using the MTT assay. One-way ANOVA followed by Tukey's post-hoc test was used to determine the statistical significance of the differences between the groups.

Effects of siMAD2L2 in combination with oxaliplatin and/or MG132 on the viability of human colorectal cancer cells.

Treatment HCT116 SW620
Negative 0.905±0.009 0.942±0.013
siMAD2L2 0.573±0.013a 0.539±0.002a
siMAD2L2 and oxaliplatin 0.270±0.005a,b 0.191±0.004a,b
siMAD2L2 and MG132 0.676±0.008a–c 0.666±0.006a–c
siMAD2L2, oxaliplatin and MG132 0.363±0.009a–d 0.377±0.0004a–d

P<0.05 vs. negative group

P<0.05 vs. siMAD2L2 group

P<0.05 vs. siMAD2L2 + oxaliplatin group

P<0.05 vs. siMAD2L2 + MG132 group. The data are presented as the mean ± SD. n=3. One-way ANOVA followed by Tukey's multiple comparisons test was used to determine statistical significance. The cells were treated with negative siRNA, siMAD2L2, siMAD2L2 + oxaliplatin, siMAD2L2 + MG132, siMAD2L2 + oxaliplatin + MG132 (oxaliplatin was incubated for 24 h at 50 and 90 µM with HCT116 and SW620 cells, respectively; MG132 was incubated for 24 h at 18 and 36 µM with HCT116 and SW620 cells, respectively). Cell viability was measured using the MTT assay. siRNA/si, small interfering RNA; MAD2L2, mitotic arrest deficient 2 like 2.

Activity of PSMD13 in human colorectal cancer cells.

Treatment HCT116 SW620
Negative 293.21±31.25 280.31±6.93
siMAD2L2 385.68±37.13a 370.62±22.43a
siMAD2L2 and oxaliplatin 485.07±44.17a,b 459.15±28.11a,b
siMAD2L2 and MG132 359.72±36.52a–c 334.73±3.71a–c
siMAD2L2, oxaliplatin and MG132 418.46±33a–d 411.28±2.67a–d

P<0.05 vs. negative group

P<0.05 vs. siMAD2L2 group

P<0.05 vs. siMAD2L2 + oxaliplatin group

P<0.05 vs. siMAD2L2 + MG132 group. One-way ANOVA followed by Tukey's multiple comparisons test was used to determine statistical significance. The data are presented as the mean ± SD. n=3. The cells were treated with negative siRNA, siMAD2L2, siMAD2L2 + oxaliplatin, siMAD2L2 + MG132, siMAD2L2 + oxaliplatin + MG132 (oxaliplatin was administered for 24 h at 50 and 90 µM to HCT116 and SW620 cells, respectively; MG132 was administered for 24 h at 18 and 36 µM to HCT116 and SW620 cells, respectively). The activity of PSMD13 was determined using an ELISA. PSMD13, proteasome 26S subunit, non-ATPase 13.